Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Shares Issued (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Shares Issued for 11 consecutive years, with $40000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Issued rose 100.03% year-over-year to $40000.0, compared with a TTM value of $67.6 million through Sep 2025, up 417.96%, and an annual FY2024 reading of $115.6 million, changed N/A over the prior year.
  • Shares Issued was $40000.0 for Q3 2025 at Avalo Therapeutics, down from $67.6 million in the prior quarter.
  • Across five years, Shares Issued topped out at $108.1 million in Q1 2024 and bottomed at -$115.6 million in Q3 2024.
  • Average Shares Issued over 5 years is $5.3 million, with a median of $32500.0 recorded in 2022.
  • Peak annual rise in Shares Issued hit 28968.0% in 2023, while the deepest fall reached 28968.0% in 2023.
  • Year by year, Shares Issued stood at $28.8 million in 2021, then tumbled by 151.34% to -$14.8 million in 2022, then grew by 7.15% to -$13.7 million in 2023, then skyrocketed by 591.71% to $67.6 million in 2024, then crashed by 99.94% to $40000.0 in 2025.
  • Business Quant data shows Shares Issued for AVTX at $40000.0 in Q3 2025, $67.6 million in Q4 2024, and -$115.6 million in Q3 2024.